Baird Downgrades Regeneron Pharmaceuticals Inc to Neutral

Brokerage firm Baird Downgrades its rating on Regeneron Pharmaceuticals Inc(NASDAQ:REGN). The shares have been rated Neutral. Previously, the analysts had a Outperform rating on the shares. The rating by Baird was issued on Aug 5, 2016.

In a different note, Bernstein said it Initiates Coverage on Regeneron Pharmaceuticals Inc, according to a research note issued on Jun 29, 2016. The shares have been rated ‘Outperform’ by the firm.

Regeneron Pharmaceuticals Inc (REGN) shares turned negative on Wednesdays trading session with the shares closing down -1.96 points or -0.47% at a volume of 4,60,727. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $415.82. The peak price level was also seen at $415.82 while the days lowest was $409. Finally the shares closed at $411.68. The 52-week high of the shares is $592.59 while the 52-week low is $329.09. According to the latest information available, the market cap of the company is $43,348 M.

Regeneron Pharmaceuticals Inc(REGN) last announced its earnings results on Aug 4, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $1.21B. Analysts had an estimated revenue of $1.24B. Earnings per share were $2.82. Analysts had estimated an EPS of $2.64.

Several Insider Transactions has been reported to the SEC. On Aug 1, 2016, Joseph L Goldstein (director) sold 2,125 shares at $425.00 per share price.Also, On Jun 16, 2016, Sanofi (10% owner) purchased 64,731 shares at $364.22 per share price.On May 25, 2016, Arthur F Ryan (director) sold 1,000 shares at $396.64 per share price, according to the Form-4 filing with the securities and exchange commission.

Regeneron Pharmaceuticals Inc. is an integrated biopharmaceutical company that discovers invents develops manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases colorectal cancer and a rare inflammatory condition and has product candidates under development in other areas including hypercholesterolemia oncology rheumatoid arthritis (RA) asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *